Neurology

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Vanqua Bio Announces Positive Interim Results from Phase 1 Clinical Trial of VQ-101, an Orally Administered, Brain-Penetrant, Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders

Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises

Findings show care for chronic liver disease patients is falling on non-specialists who need stronger education and support to ensure...

Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four...

Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries

ISTANBUL and LONDON, and BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the...

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting...

Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board

INGLEWOOD, California, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognos Therapeutics, a private hi-tech medical technology company focused on the development...

error: Content is protected !!